Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma

References

• Australian Cancer Network Colorectal Cancer Guidelines Revision Comittee. Guidelines for the Prevention, Early Detection and Management of Colorectal Cancer. 2nd ed. Sydney: Australian Cancer Network, 2005. http://www.cancer.org.au/Healthprofessionals/clinicalguidelines/colorectalcancer.htm
   Google Scholar
• Yantiss RK, Goodarzi M, Zhou XK, et al Clinical, pathologic, and molecular features of early-onset colorectal carcinoma. Am J Surg Pathol 2009; 33: 572–582.
   PubMed Web of Science ®Google Scholar
• Boland CR, Koi M, Chang DK, et al The biochemical basis of microsatellite instability and abnormal immunohistochemistry and clinical behavior in Lynch syndrome: from bench to bedside. Fam Cancer 2008; 7: 41–52.
   PubMed Web of Science ®Google Scholar
• Yang G, Scherer SJ, Shell SS, et al Dominant effects of an Msh6 missense mutation on DNA repair and cancer susceptibility. Cancer Cell 2004; 6: 139–150.
   PubMed Web of Science ®Google Scholar
• Carethers JM, Hawn MT, Chauhan DP, et al Competency in mismatch repair prohibits clonal expansion of cancer cells treated with N-methyl-N′-nitro-N-nitrosoguanidine. J Clin Invest 1996; 98: 199–206.
   PubMed Web of Science ®Google Scholar
• Plotz G, Welsch C, Giron-Monzon L, et al Mutations in the MutSalpha interaction interface of MLH1 can abolish DNA mismatch repair. Nucleic Acids Res 2006; 34: 6574–6586.
   PubMed Web of Science ®Google Scholar
• Perucho M. Microsatellite instability: the mutator that mutates the other mutator. Nat Med 1996; 2: 630–631.
   PubMed Web of Science ®Google Scholar
• Smolarz B, Romanowicz-Makowska H, Langner E, et al Genetic analysis of microsatellite markers in patients from hereditary nonpolyposis colorectal cancer (HNPCC) families. Exp Oncol 2004; 26: 205–209.
   PubMedGoogle Scholar
• Poynter JN, Siegmund KD, Weisenberger DJ, et al Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening. Cancer Epidemiol Biomarkers Prev 2008; 17: 3208–3215.
   PubMed Web of Science ®Google Scholar
• Loughrey MB, Waring PM, Tan A, et al Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer. Fam Cancer 2007; 6: 301–310.
   PubMed Web of Science ®Google Scholar
• Bettstetter M, Dechant S, Ruemmele P, et al Distinction of hereditary nonpolyposis colorectal cancer and sporadic microsatellite-unstable colorectal cancer through quantification of MLH1 methylation by real-time PCR. Clin Cancer Res 2007; 13: 3221–3228.
   PubMed Web of Science ®Google Scholar
• Shia J, Tang LH, Vakiani E, et al Immunohistochemistry as first-line screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: a 2-antibody panel may be as predictive as a 4-antibody panel. Am J Surg Pathol 2009; 33: 1639–1645.
   PubMed Web of Science ®Google Scholar
• Umar A, Boland CR, Terdiman JP, et al Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004; 96: 261–268.
   PubMed Web of Science ®Google Scholar
• Watson N, Grieu F, Morris M, et al Heterogeneous staining for mismatch repair proteins during population-based prescreening for hereditary nonpolyposis colorectal cancer. J Mol Diagn 2007; 9: 472–478.
   PubMedGoogle Scholar
• Hampel H, Frankel WL, Martin E, et al Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 2008; 26: 5783–5788.
   PubMed Web of Science ®Google Scholar
• Iacopetta B, Li WQ, Grieu F, et al BRAF mutation and gene methylation frequencies of colorectal tumours with microsatellite instability increase markedly with patient age. Gut 2006; 55: 1213–1214.
   PubMedGoogle Scholar
• Clark AJ, Barnetson R, Farrington SM, et al Prognosis in DNA mismatch repair deficient colorectal cancer: are all MSI tumours equivalent? Fam Cancer 2004; 3: 85–91.
   PubMedGoogle Scholar
• Southey MC, Jenkins MA, Mead L, et al Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer. J Clin Oncol 2005; 23: 6524–6532.
   PubMedGoogle Scholar
• Truninger K, Menigatti M, Luz J, et al Immunohistochemical analysis reveals high frequency of PMS2 defects in colorectal cancer. Gastroenterology 2005; 128: 1160–1171.
   PubMed Web of Science ®Google Scholar